Toripalimab Combined With Beat Chemotherapy in the Treatment of Advanced Back-line Small Cell Lung Cancer

This study is a randomized, open-label, multi-center investigator-initiated clinical trial. Patients who meet the inclusion criteria receive the treatment plan stipulated in the protocol. A Bayesian design is used to explore the efficacy and safety of teprotumumab combined with pulse chemotherapy in the treatment of advanced second-line extensive-stage small cell lung cancer.

NCT Number	NCT07698054
Lead Sponsor	Henan Cancer Hospital
Conditions	SCLC, Extensive Stage, Bayesian, Metronomic Chemotherapy
Enrollment	130 participants
Start Date	2026-08-01
Primary Completion	2030-01-01 (estimated)
Study Completion	2030-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-07-13